View ValuationHansoh Pharmaceutical Group 향후 성장Future 기준 점검 2/6Hansoh Pharmaceutical Group (는) 각각 연간 10% 및 10.9% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 9.9% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 15.5% 로 예상됩니다.핵심 정보10.0%이익 성장률9.91%EPS 성장률Pharmaceuticals 이익 성장24.0%매출 성장률10.9%향후 자기자본이익률15.47%애널리스트 커버리지Good마지막 업데이트24 Jul 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updates공고 • Jul 10Hansoh Pharmaceutical Group Company Limited Reports Positive Phase III Results For Risvutatug Rezetecan In Small-Cell Lung CancerGSK plc licensor Hansoh Pharmaceutical Group Co. Ltd. announced that ARTEMIS-008, its pivotal phase III trial evaluating risvutatug rezetecan (Ris-Rez) in patients with advanced or relapsed small-cell lung cancer (SCLC), met its primary endpoint of overall survival (OS). In the trial, conducted in patients in China, Ris-Rez demonstrated statistically significant and clinically meaningful improvements in OS compared with the standard of care, topotecan. Consistent benefit was also observed across key secondary endpoints, including progression-free survival. These data will be used by Hansoh Pharma for regulatory submission in China. These are the first positive phase III overall survival data reported for a B7-H3-targeted antibody-drug conjugate (ADC) in any tumour type. The safety profile is consistent with prior Ris-Rez findings, and no new safety signals were identified. GSK holds exclusive global rights to develop Ris-Rez outside mainland China, Hong Kong, Macau and Taiwan. GSK's broad clinical development programme includes studies in lung cancer, prostate cancer and other solid tumours, including the global phase III EMBOLD SCLC-301 trial in relapsed extensive-stage small-cell lung cancer (ES-SCLC) with pivotal data expected next year. Most patients with ES-SCLC relapse after initial therapy and have limited treatment options, poor prognosis and significant treatment burden. B7-H3 is highly expressed in SCLC tumours and the positive results from ARTEMIS-008 add to the growing body of evidence supporting the encouraging clinical activity and manageable safety profile of Ris-Rez in patients with ES-SCLC. Ris-Rez is a novel investigational B7-H3-targeted ADC composed of a fully human anti-B7-H3 monoclonal antibody covalently linked to a topoisomerase inhibitor payload. GSK acquired exclusive worldwide rights (excluding China's mainland, Hong Kong, Macau, and Taiwan) from Hansoh Pharma to progress clinical development and commercialisation of Ris-Rez. Regulatory designations received for Ris-Rez to date include orphan drug designations from the US Food and Drug Administration (FDA) and Japan's Ministry of Health, Labour and Welfare in SCLC and the European Medicines Agency (EMA) in a category of cancer that includes SCLC, called pulmonary neuroendocrine carcinoma; Priority Medicines (PRIME) Designation from the EMA for relapsed or refractory ES-SCLC; and Breakthrough Therapy Designations for relapsed or refractory ES-SCLC and relapsed or refractory osteosarcoma from the US FDA.Valuation Update With 7 Day Price Move • Jul 03Investor sentiment improves as stock rises 18%After last week's 18% share price gain to €3.69, the stock trades at a forward P/E ratio of 30x. Average forward P/E is 20x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 162% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €6.84 per share.Upcoming Dividend • Jun 26Upcoming dividend of HK$0.20 per shareEligible shareholders must have bought the stock before 03 July 2026. Payment date: 24 July 2026. Payout ratio is a comfortable 42% and this is well supported by cash flows. Trailing yield: 1.5%. Lower than top quartile of German dividend payers (4.8%). Lower than average of industry peers (2.6%).New Risk • Jun 07New minor risk - Dividend sustainabilityThe company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 1.5% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company.공고 • Jun 04Hansoh Pharmaceutical Group Company Limited, Annual General Meeting, Jun 26, 2026Hansoh Pharmaceutical Group Company Limited, Annual General Meeting, Jun 26, 2026, at 10:00 China Standard Time. Location: 50/f, office tower, convention plaza, 1 harbour road, wan chai, Hong KongBoard Change • May 20Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 3 highly experienced directors. Independent Non-Executive Director Jia Yan was the last director to join the board, commencing their role in 2025. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.공고 • Mar 18Hansoh Pharmaceutical Group Company Limited to Report Fiscal Year 2025 Results on Mar 29, 2026Hansoh Pharmaceutical Group Company Limited announced that they will report fiscal year 2025 results at 9:30 AM, China Standard Time on Mar 29, 2026공고 • Feb 21Hansoh Pharmaceutical Group Company Limited Announces Approval in the European Union as MonotherapyThe board of directors of Hansoh Pharmaceutical Group Company Limited announced that, on February 12, 2026, Aumolertinib Mesylate Tablets, marketed as Ameile in China and Aumseqa outside China, the Group's innovative drug, has been approved in the European Union as monotherapy for: (i) the first-line treatment of adult patients with advanced non-small cell lung cancer ("NSCLC") whose tumours have epidermal growth factor receptor ("EGFR") exon 19 deletions or exon 21 (L858R) substitution mutations; and (ii) the treatment of adult patients with advanced EGFR T790M mutation-positive NSCLC. The approval by the European Commission (EC) follows the positive opinion of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).공고 • Jan 08Hansoh Pharmaceutical Group Company Limited Announces Drug Registration Approval of the Fifth Indication of Ameile (Aumolertinib Mesylate Tablets) Was Granted by the National Medical Products AdministrationThe board of directors of Hansoh Pharmaceutical Group Company Limited announced that, the Group's innovative drug Ameile (Aumolertinib Mesylate Tablets) has been granted drug registration approval by the National Medical Products Administration (" NMPA") of China, approving the addition of an indication: Ameile in combination with pemetrexed and platinum-based chemotherapy to be used as the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer ("NSCLC") whose tumors have epidermal growth factor receptor (" EGFR") exon 19 deletions or exon 21 (L858R) mutations. This is the fifth indication of Ameile which has been approved.공고 • Aug 21Hansoh Pharmaceutical Group Company Limited has filed a Follow-on Equity Offering in the amount of HKD 3.9204 billion.Hansoh Pharmaceutical Group Company Limited has filed a Follow-on Equity Offering in the amount of HKD 3.9204 billion. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 108,000,000 Price\Range: HKD 36.3 Transaction Features: Subsequent Direct Listing공고 • Aug 07Hansoh Pharmaceutical Group Company Limited to Report First Half, 2025 Results on Aug 18, 2025Hansoh Pharmaceutical Group Company Limited announced that they will report first half, 2025 results on Aug 18, 2025공고 • Jun 05Hansoh Pharmaceutical Group Company Limited Announces Approval of Aumolertinib Mesilate Tablets by the Medicines and Healthcare Products Regulatory Agency for MarketingThe board of directors of Hansoh Pharmaceutical Group Company Limited announced that, Aumolertinib Mesilate Tablets (trade name in the UK: Aumseqa®?), the Group's innovative drug, has been approved by the Medicines and Healthcare Products Regulatory Agency ("MHRA") in the UK for marketing. Aumseqa®? as monotherapy is indicated for: the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer ("NSCLC") with activating epidermal growth factor receptor (" EGFR") mutations, and the treatment of adult patients with locally Advanced or metastatic EGFR T790M mutation-positive NSCLC.공고 • May 31Hansoh Pharmaceutical Group Company Limited Announces the Third Biologics License Application of Xin Yue (Inebilizumab Injection) Has Been Accepted by the National Medical Products AdministrationThe board of directors of Hansoh Pharmaceutical Group Company Limited announced that, on May 29, 2025, the third biologics license application ("BLA") of XINYUE (Xin Yue ®?) (Inebilizumab Injection) (the "Product") has been accepted by the National Medical Products Administration (the "NMPA"), which is for the treatment of generalized myasthenia gravis (gMG) in adult patients.공고 • May 30+ 1 more updateHansoh Pharmaceutical Group Company Limited Obtains Clinical Trial Approval Issued by the National Medical Products AdministrationThe board of directors of Hansoh Pharmaceutical Group Company Limited announce that, HS-10542 capsules, a Category 1 innovative drug self-developed by the Group, has obtained the Clinical Trial Approval issued by the National Medical Products Administration (NMPA) of China, which is intended to be investigated in clinical trials for paroxysmal nocturnal hemoglobinuria (PNH), and immunoglobulin A nephropathy (IgAN).공고 • May 29+ 1 more updateHansoh Pharmaceutical Group Company Limited, Annual General Meeting, Jun 20, 2025Hansoh Pharmaceutical Group Company Limited, Annual General Meeting, Jun 20, 2025, at 10:00 China Standard Time. Location: 50/f, office tower, convention plaza, 1 harbour road, wan chai, Hong Kong공고 • Apr 17National Medical Products Administration Grants Breakthrough-Therapy-Designated Drug for B7-H3-Targeted Antibody-Drug Conjugate Hs-20093 for InjectionHansoh Pharmaceutical Group Company Limited announced that, on April 17, 2025, the Group's self-developed B7-H3-targeted antibody-drug conjugate ("ADC") HS-20093 for injection has obtained approval to be included as Breakthrough-Therapy-Designated Drug by the National Medical Products Administration (" NMPA") of China, with the proposed indication for locally advanced or metastatic non-squamous non-small cell lung cancer without driver mutations, progressed or recurred following platinum-based chemotherapy.공고 • Apr 15Hansoh Pharmaceutical Group Company Limited Obtains Clinical Trial Approval for Hs-10529 TabletsThe board of directors of Hansoh Pharmaceutical Group Company Limited announced that, HS-10529 tablets, a Small Molecule Category I Innovative Drug targeting KRAS G12D self-developed by the Group, has obtained the Clinical Trial Approval issued by the National Medical Products Administration (NMPA) of China, which is intended to be investigated in clinical trials for advanced solid tumors (pancreatic cancer, colorectal cancer, non-small cell lung cancer, etc.) with KRAS G12D mutations.공고 • Apr 07+ 1 more updateHansoh Pharmaceutical Group Company Limited Obtains Clinical Trial Approval for HS-20108 for InjectionThe board of directors of Hansoh Pharmaceutical Group Company Limited announced that, innovative drug HS-20108 for injection, self-developed by the Group, has obtained the Clinical Trial Approval issued by the National Medical Products Administration (NMPA) of China recently, which is intended to be investigated in clinical trials for advanced solid tumors such as small cell lung cancer and neuroendocrine tumors.공고 • Mar 21Hansoh Pharmaceutical Group Company Limited Proposes Final Ordinary Dividend for the Year Ended December 31, 2024, Payable on July 25, 2025Hansoh Pharmaceutical Group Company Limited proposed final ordinary dividend of HKD 0.1353 per share for the year ended December 31, 2024. Ex-dividend date: July 3, 2025. Record date: July 9, 2025. Payment date: July 25, 2025.공고 • Mar 20TiumBio Co., Ltd.'s Partner Hansoh Pharma Expands Indications for Merigolix (HS-10518) with Initiation of ART (Assisted Reproductive Technology) DevelopmentTiumBio Co. Ltd. announced that its partner, Hansoh Pharma, has expanded the clinical indications of merigolix (Hansoh's code: HS-10518), an oral gonadotropin-releasing hormone receptor antagonist. Orally administered merigolix may be important in the control of premature endogenous LH surge and in reducing the cycle cancellation rate, with an improvement of pregnancy rate per cycle. Currently, in COS regimens, gonadotropin-re releasing hormone (GnRH) products are only available in injectable form, which caused the pain and relatively high cost. Meanwhile, merigolix is an oral GnRH receptor antagonist being developed for the treatment of endometriosis,uterine fibroids, and ART. TiumBio entered into a licensing agreement with Hansoh Pharma for merigolix for up to $170 million plus tiered royalties upon net sales. Under the terms of the agreement, Hansoh Pharma obtained exclusive rights to develop and commercialize merigolix in Greater China.공고 • Mar 10Hansoh Pharmaceutical Group Company Limited to Report Fiscal Year 2024 Results on Mar 21, 2025Hansoh Pharmaceutical Group Company Limited announced that they will report fiscal year 2024 results on Mar 21, 2025공고 • Mar 05Hansoh Pharmaceutical Group Company Limited Announces Acceptance of Second Biologics License Application by the National Medical Products AdministrationThe board of directors of Hansoh Pharmaceutical Group Company Limited announced that, on March 4, 2025, the second Biologics License Application (BLA) of XINYUE (Inebilizumab Injection) has been accepted by the National Medical Products Administration (the "NMPA"), which is for the treatment of immunoglobulin G4-related disease (IgG4-RD). On February 8, 2025, this indication has been included in the Priority Review and Approval Procedure by the NMPA. Inebilizumab is a targeted CD19 B cell-depleting antibody. On May 24, 2019, the Group entered into a license agreement with Viela Bio (Viela Bio was acquired by Horizon Therapeutics in 2021, which was acquired by Amgen in 2023), and has been granted an exclusive license to develop and commercialize the Product in China's mainland, Hong Kong and Macao. On March 14, 2022, the Product was approved to be launched in China by NMPA for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive. In January 2023, the Product was included in the National Reimbursement Drug List for the first time, and this inclusion was successfully renewed in November 2024.공고 • Feb 25+ 1 more updateNational Medical Products Administration Grants Breakthrough-Therapy-Designated Drug for B7-H3-T Targeted Antibody-Drug Conjugate HS-20093 for Osteosarcoma of Hansoh Pharmaceutical Group Company LimitedThe board of directors of Hansoh Pharmaceutical Group Company Limited announced that on February 25, 2025, the Group's self-developed B7-H3-targeted antibody-drug conjugate ("ADC") HS-20093 for injection has obtained approval to be included as Breakthrough-Therapy-Designated Drug by the National Medical Products Administration of China, with the proposed indication for the treatment of patients with osteosarcoma who have progressed on at least two prior lines of therapy. HS-20093 is an investigational B7-H3-targeted ADC composed of a fully human anti-B7-H3 monoclonal antibody covalently linked to topoisomerase inhibitor (TOPOi) payload and being developed for the treatment of lung cancer, sarcoma, head and neck cancers and other solid tumors in multiple clinical trials in China, with the highest research stage being Phase III clinical trials. On November 1, 2024, the NMPA listed HS-20093 as a Breakthrough-Therapy-Designated Drug, with the indication being extensive-stage small-cell lung cancer (ES-SCLC) developed after standard first-line treatment (platinum doublet chemotherapy combined with immuno-therapy).공고 • Feb 10Hansoh Pharmaceutical Group Company Limited Announces New Indication of Xin Yue (Inebilizumab Injection) Included in Priority Review and Approval Procedure by the National Medical Products AdministrationThe board of directors of Hansoh Pharmaceutical Group Company Limited announced that, on February 8, 2025, based on the positive results from the global pivotal Phase III MITIGATE trial on XINYUE (Xin Yue ®?) (Inebilizumab Injection) (the Product), the new indication of the treatment of immunoglobulin G4-related disease (IgG4-RD) of the Product has been included in the Priority Review and Approval Procedure by the National Medical Products Administration (the NMPA).공고 • Jan 24Hansoh Pharmaceutical Group Company Limited Announces Changes to Company SecretaryThe board of directors of Hansoh Pharmaceutical Group Company Limited announced that, with effect from January 24, 2025, due to personal work arrangement, Ms. Tam Sze Wai Sara has tendered her resignation as a joint company secretary of the Company and ceased to be an authorized representative of the Company under Rule 3.05 of the Rule Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules") and the process agent of the Company in Hong Kong for the purpose of accepting service of process and notices on its behalf as required under Rule 19.05(2) of the Listing Rules and Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) (the "Process Agent"). Following the resignation of Ms. Tam, the Board announces that Ms. Wong Yuen Ki (" Ms. Wong") has been appointed as the joint company secretary with effect from January 24, 2025. Ms. Wong is a senior manager of corporate services of Tricor Services Limited. Ms. Wong possesses more than 10 years of experience in the company secretarial field. Ms. Wong is a Chartered Secretary, a Chartered Governance Professional and an associate of both The Hong Kong Chartered Governance Institute and The Chartered Governance Institute. Ms. Wong holds a degree of Bachelor of Business Administration in Corporate Administration and degree of Master of Corporate Governance from Hong Kong Metropolitan University. Ms. Wong possesses the academic or professional qualifications of a company secretary as required under Rule 3.28 of the Listing Rules. With effect from January 24, 2025, the joint company secretaries of the Company are Ms. Zhong Shengli and Ms. Wong.Board Change • Dec 30Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 3 highly experienced directors. Independent Non-Executive Director Guoqiang Lin was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.공고 • Nov 27Hansoh Pharmaceutical Group Company Limited Announces the Fifth New Drug Application of Ameile (Aumolertinib Mesilate Tablets) Was Accepted by the National Medical Products AdministrationHansoh Pharmaceutical Group Company Limited announced that, the fifth New Drug Application ("NDA") of the Group's innovative drug Ameile (A Mei Le ®?) (Aumolertinib Mesilate Tablets) has been accepted by the National Medical Products Administration of China ("NMPA"). The indication is that Ameile in combination with pemetrexed and platinum-based chemotherapy to be used as the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer ("NSCLC") whose tumors have epidermal growth factor receptor (" EGFR") exon 19 deletions or exon 21 (L858R) mutations. . Ameile (Aumolertinib Mesilate Tablets) is the first innovative third-generation EGFR-TKI drug wholly developed in China. In March 2020, Ameile obtained approval for the treatment of patients with locally advanced or metastatic NSCLC with T790M mutation, who have progressed on or after EGFR-TKI therapy. In December 2021, Ameile obtained approval to be used as the first-line treatment for adult patients with locally advanced or metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitute mutation positive. In July 2024, the NDA of Ameile for adjuvant therapy after tumor resection in patients with NSCLC whose tumors have EGFR exon 19 deletions or exon 21 (L858R) mutations was accepted by the NMPA. In August 2024, the NDA of Ameile for the treatment in patients with locally advanced, unresectable, EGFR exon 19 deletions or exon 21 (L858R) mutations, NSCLC without progression following definitive platinum-based chemoradiotherapy was accepted by the NMPA.Valuation Update With 7 Day Price Move • Nov 01Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to €2.02, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 14x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 20% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €3.33 per share.공고 • Nov 01Hansoh Pharmaceutical Group Company Limited Announces the NMPA Has Granted Breakthrough-Therapy-Designated Drug for B7-H3-Targeted Antibody-Drug Conjugate HS-20093The board of directors of Hansoh Pharmaceutical Group Company Limited announced that on November 1, 2024, the Group's self-developed B7-H3-targeted antibody-drug conjugate (‘ADC’) HS-20093 for injection has obtained approval to be included as Breakthrough-Therapy-Designated Drug by the National Medical Products Administration (‘NMPA’) of China, with the proposed indication being extensive stage small cell lung cancer (‘ES-SCLC’) developed after standard first-line treatment (platinum doublet chemotherapy combined with immuno-therapy).공고 • Oct 22Hansoh Pharmaceutical Group Company Limited Announces Phase III Registrational Trial AENEAS2 Evaluating Ameile in Combination with Chemotherapy for Patients with Locally Advanced or Metastatic EGFR-Mutated NSCLCThe board of directors of Hansoh Pharmaceutical Group Company Limited announced that Phase III registrational trial AENEAS2 evaluating Ameile in combination with chemotherapy as first line therapy for patients with locally advanced (Stage IIIB~IIIC) or metastatic (Stage IV) epidermal growth factor receptor mutated non-small cell lung cancer met its primary endpoint of progression-free survival .AMEILE combined with chemotherapy demonstrated statistically significant and clinically meaningful improvement in PFS in patients with EGFR mutated advanced lung cancer. Detailed results of the study will be presented at upcoming medical conference and will be submitted to regulatory authority. Ameile (Aumolertinib Mesilate Tablets) is the first innovative third-generation EGFR-TKI drug wholly developed in China. In March 2020, Ameile obtained approval for the treatment of patients with locally advanced or metastatic NSCLC with T790M mutation, who have progressed on or after EGFR-TKI therapy, and was also successfully renewed in the 2022 National Reimbursement Drug List ("NRDL") in January 2023. In December 2021, Ameile obtained approval to be used as the first-line treatment for adult patients with locally advanced or metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitute mutation positive, and has been included in the 2022 NRDL in January 2023. In July 2024, the New Drug Application ("NDA") of Ameile for adjuvant therapy after tumor resection in patients with NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations was accepted by the National Medical Products Administration (" NMPA "). In August 2024, the NDA of Ameile for the treatment in patients with locally advanced, unresectable, EGFR exon 19 deletions or exon 21 (L858R) mutations, NSCLC without progression following definitive platinum-based chemoradiotherapy was accepted by the NMPA.New Risk • Oct 09New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 2.5% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 2.5% per year for the foreseeable future. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (10% average weekly change). Significant insider selling over the past 3 months (€69m sold).Valuation Update With 7 Day Price Move • Oct 03Investor sentiment improves as stock rises 22%After last week's 22% share price gain to €2.66, the stock trades at a forward P/E ratio of 29x. Average forward P/E is 14x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 42% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €3.63 per share.Reported Earnings • Sep 27First half 2024 earnings released: EPS: CN¥0.46 (vs CN¥0.22 in 1H 2023)First half 2024 results: EPS: CN¥0.46 (up from CN¥0.22 in 1H 2023). Revenue: CN¥6.51b (up 44% from 1H 2023). Net income: CN¥2.73b (up 112% from 1H 2023). Profit margin: 42% (up from 29% in 1H 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.Upcoming Dividend • Sep 13Upcoming dividend of HK$0.20 per shareEligible shareholders must have bought the stock before 20 September 2024. Payment date: 30 October 2024. Payout ratio is a comfortable 40% and this is well supported by cash flows. Trailing yield: 2.1%. Lower than top quartile of German dividend payers (4.9%). Higher than average of industry peers (1.1%).Declared Dividend • Aug 29First half dividend of HK$0.20 announcedShareholders will receive a dividend of HK$0.20. Ex-date: 20th September 2024 Payment date: 30th October 2024 Dividend yield will be 9.3%, which is higher than the industry average of 2.4%. Sustainability & Growth Dividend is covered by both earnings (40% earnings payout ratio) and cash flows (79% cash payout ratio). The dividend has increased by an average of 78% per year over the past 3 years and payments have been stable during that time. EPS is expected to decline by 8.3% over the next 3 years. However, it would need to fall by 56% to increase the payout ratio to a potentially unsustainable range.Reported Earnings • Aug 28First half 2024 earnings released: EPS: CN¥0.46 (vs CN¥0.22 in 1H 2023)First half 2024 results: EPS: CN¥0.46 (up from CN¥0.22 in 1H 2023). Revenue: CN¥6.51b (up 44% from 1H 2023). Net income: CN¥2.73b (up 112% from 1H 2023). Profit margin: 42% (up from 29% in 1H 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 7.9% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.공고 • Aug 27Hansoh Pharmaceutical Group Company Limited Announces an Interim Dividend for the Six Months Ended June 30, 2024, Payable on 30 October 2024Hansoh Pharmaceutical Group Company Limited announced an interim dividend of HKD 0.201 per share for the six months ended June 30, 2024. Ex-dividend date is 20 September 2024. Record date is 25 September 2024. Payment date is 30 October 2024.공고 • Aug 15Hansoh Pharmaceutical Group Company Limited to Report First Half, 2024 Results on Aug 27, 2024Hansoh Pharmaceutical Group Company Limited announced that they will report first half, 2024 results on Aug 27, 2024공고 • Jul 20Hansoh Pharmaceutical Group Company Limited Announces New Drug Application of Ammeile for the Adjuvant Treatment of Egfr Mutation-Positive Non-Small Cell Lung Cancer Accepted by the National Medical Products Administration of the People's Republic of ChinaThe board of directors of Hansoh Pharmaceutical Group Company Limited announced that the New Drug Application of "Ameile" (A Mei Le ®?) for adjuvant therapy after tumor resection in patients with non-small cell lung cancer ("NSCLC") whose tumors have epidermal growth factor receptor ("EGFR") exon 19 deletions or exon 21 L858R mutations, was accepted by the National Medical Products Administration of the People's Republic of China. Ameile is a category 1 innovative drug developed by Jiangsu Hansoh Pharmaceutical Group Co. Ltd. ("J Jiang Su Hao Sen Yao Ye Ji Tuan You Xian Gong Si"), a subsidiary of the Company. The said application will be the third indication of Ameile.Buy Or Sell Opportunity • Jul 02Now 27% undervaluedThe stock has been flat over the last 90 days, currently trading at €1.86. The fair value is estimated to be €2.55, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 2.9% over the last 3 years. Earnings per share has grown by 3.9%. For the next 3 years, revenue is forecast to grow by 9.1% per annum. Earnings are also forecast to grow by 8.6% per annum over the same time period.Buy Or Sell Opportunity • Jun 19Now 21% undervaluedOver the last 90 days, the stock has risen 15% to €1.97. The fair value is estimated to be €2.48, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 2.9% over the last 3 years. Earnings per share has grown by 3.9%. For the next 3 years, revenue is forecast to grow by 9.1% per annum. Earnings are also forecast to grow by 8.6% per annum over the same time period.Upcoming Dividend • Jun 12Upcoming dividend of HK$0.14 per shareEligible shareholders must have bought the stock before 19 June 2024. Payment date: 17 July 2024. Payout ratio is a comfortable 35% and this is well supported by cash flows. Trailing yield: 1.6%. Lower than top quartile of German dividend payers (4.6%). Lower than average of industry peers (2.2%).공고 • May 01Hansoh Pharmaceutical Group Company Limited, Annual General Meeting, Jun 13, 2024Hansoh Pharmaceutical Group Company Limited, Annual General Meeting, Jun 13, 2024, at 10:00 China Standard Time. Location: 10/F United Centre, 95 Queensway Admiralty Hong Kong Agenda: To receive and adopt the audited consolidated financial statements of the Company and the reports of the directors and auditors for the year ended December 31, 2023; to approve the payment of a final dividend for the year ended December 31, 2023; to re-elect Dr. Lyu Aifeng as executive director; to re-elect Mr. Lin Guoqiang as independent non-executive director; to authorize the board of directors to fix the respective directors' remuneration; to re-appoint Ernst & Young as auditors and to authorize the board of directors to fix their remuneration; and to transact other business.Reported Earnings • Apr 30Full year 2023 earnings released: EPS: CN¥0.55 (vs CN¥0.44 in FY 2022)Full year 2023 results: EPS: CN¥0.55 (up from CN¥0.44 in FY 2022). Revenue: CN¥10.1b (up 7.7% from FY 2022). Net income: CN¥3.28b (up 27% from FY 2022). Profit margin: 32% (up from 28% in FY 2022). Post-clinical trial products Approved (during full year): 6 Revenue is forecast to grow 8.9% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.공고 • Apr 30Hansoh Pharmaceutical Group Company Limited Announces Executive Changes, Effective April 29, 2024Hansoh Pharmaceutical Group Company Limited announced that, with effect from April 29, 2024, Ms. Li Yan Wing Rita (Ms. Li) has tendered her resignation as a joint company secretary of the company and ceased to be an authorized representative of the company (the Authorized Representative) under Rule 3.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the process agent of the company in Hong Kong for the purpose of accepting service of process and notices on its behalf as required under Rule 19.05(2) of the Listing Rules and Part 16 of the Companies Ordinance. Following the resignation of Ms. Li, the board announced that Ms. Tam Sze Wai Sara (Ms. Tam) has been appointed as a joint company secretary with effect from April 29, 2024. Ms. Tam is currently a manager of Corporate Services of Tricor Services Limited. She has over 10 years of experience in the corporate secretarial field and has been providing professional corporate services to Hong Kong listed companies as well as multinational, private and offshore companies. Ms. Tam is a Chartered Secretary, a Chartered Governance Professional and an associate of both The Hong Kong Chartered Governance Institute and The Chartered Governance Institute. Following the resignation of Ms. Li, she has also ceased to be an Authorized Representative and the Process Agent with effect from April 29, 2024. The Board announced that Ms. Tam, the newly appointed joint company secretary, has been appointed as an Authorized Representative and the Process Agent with effect from April 29, 2024.Buy Or Sell Opportunity • Apr 29Now 21% undervaluedOver the last 90 days, the stock has risen 39% to €2.00. The fair value is estimated to be €2.53, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 2.9% over the last 3 years. Earnings per share has grown by 3.9%. For the next 3 years, revenue is forecast to grow by 8.9% per annum. Earnings are also forecast to grow by 8.7% per annum over the same time period.공고 • Apr 03Hansoh Pharmaceutical Group Company Limited, Jiangsu Hansoh Pharmaceutical Group Company Limited and Shanghai Hansoh Biomedical Technology Company Limited Receives Grant of A Clinical Trial Notice Issued by the National Medical Products Administration of the People's Republic of China to Be Used for the Treatment of Advanced Non-Small Cell Lung CancerThe board of directors of Hansoh Pharmaceutical Group Company Limited announced that "HS- 10504 tablets", a Category 1 innovative drug self-developed by Jiangsu Hansoh Pharmaceutical Group Company Limited and Shanghai Hansoh Biomedical Technology Company Limited, both being subsidiaries of the Company, has been granted a clinical trial notice issued by the National Medical Products Administration of the People's Republic of China, and is intended to be used for the treatment of advanced non-small cell lung cancer. The specific indication will be determined after the completion of clinical research.New Risk • Mar 28New minor risk - Dividend sustainabilityThe company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 1.8% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (10% average weekly change). Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.Reported Earnings • Mar 27Full year 2023 earnings released: EPS: CN¥0.55 (vs CN¥0.44 in FY 2022)Full year 2023 results: EPS: CN¥0.55 (up from CN¥0.44 in FY 2022). Revenue: CN¥10.1b (up 7.7% from FY 2022). Net income: CN¥3.28b (up 27% from FY 2022). Profit margin: 32% (up from 28% in FY 2022). Revenue is forecast to grow 9.9% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.공고 • Mar 15Hansoh Pharmaceutical Group Company Limited to Report Fiscal Year 2023 Results on Mar 26, 2024Hansoh Pharmaceutical Group Company Limited announced that they will report fiscal year 2023 results on Mar 26, 2024Valuation Update With 7 Day Price Move • Feb 17Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €1.59, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 16x in the Pharmaceuticals industry in Germany. Total loss to shareholders of 62% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €2.29 per share.Board Change • Jan 25Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 2 highly experienced directors. Independent Non-Executive Director Guoqiang Lin was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.공고 • Jan 17Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of HS-10509 TabletsThe board of directors of Hansoh Pharmaceutical Group Company Limited announced that "HS-10509 tablets", a Category 1 innovative drug self-developed by Jiangsu Hansoh Pharmaceutical Group Company Limited and Shanghai Hansoh Biomedical Technology Company Limited, both being subsidiaries of the Company, has been granted a clinical trial notice issued by the National Medical Products Administration of the People's Republic of China, and is intended to be used for the treatment of schizophrenia. The specific indication will be determined after the completion of clinical research.공고 • Nov 11Shanghai Hansoh Biomedical Technology Company Limited and Jiangsu Hansoh Pharmaceutical Group Company Limited Receives Clinical Trial NoticeThe board of directors of Hansoh Pharmaceutical Group Company Limited announced that "HS-10511 tablets", a Category 1 innovative drug self-developed by Shanghai Hansoh Biomedical Technology Company Limited ("Shang Hai Han Sen Sheng Wu Yi Yao Ke Ji You Xian Gong Si") and Jiangsu Hansoh Pharmaceutical Group Company Limited ("Jiang Su Hao Sen Yao Ye Ji Tuan You Xian Gong Si"), both being subsidiaries of the Company, has been granted a clinical trial notice issued by the National Medical Products Administration of the People's Republic of China, and is intended to be used for the treatment of hypertrophic cardiomyopathy (HCM). The specific indication will be determined after the completion of clinical research.Valuation Update With 7 Day Price Move • Oct 28Investor sentiment improves as stock rises 24%After last week's 24% share price gain to €1.70, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 16x in the Pharmaceuticals industry in Germany. Total loss to shareholders of 52% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €1.85 per share.New Risk • Oct 25New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 8.6% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.공고 • Oct 20Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of Hs-20106 InjectionsHansoh Pharmaceutical Group Company Limited announced that "HS-20106 Injections" (the "Product"), a Category 1 therapeutic biological product has been granted a clinical trial notice issued by the National Medical Products Administration of the People's Republic of China. The specific indication will be determined after the completion of clinical research.Reported Earnings • Oct 01First half 2023 earnings released: EPS: CN¥0.22 (vs CN¥0.22 in 1H 2022)First half 2023 results: EPS: CN¥0.22 (down from CN¥0.22 in 1H 2022). Revenue: CN¥4.51b (up 1.7% from 1H 2022). Net income: CN¥1.29b (flat on 1H 2022). Profit margin: 29% (in line with 1H 2022). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 3.5% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings.공고 • Sep 26Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of "HS-20105"The board of directors of Hansoh Pharmaceutical Group Company Limited announced that "HS-20105", a Category 1 therapeutic biological product self-developed by Shanghai Hansoh Biomedical Technology Company Limited ("Shang Hai Han Sen Sheng Wu Yi Yao Ke Ji You Xian Gong Si") and Changzhou Hansoh Pharmaceutical Company Limited ("Ch Chang Zhou Heng Bang Yao Ye You Xian Gong Si"), both being subsidiaries of the Company, has been granted a clinical trial notice issued by the National Medical Products Administration of the People's Republic of China, and is intended to be used for the treatment of advanced solid tumors. The specific indication will be determined after the completion of clinical research.공고 • Sep 02Hansoh Pharmaceutical Group Company Limited Announces Interim Dividend for the Six Months Ended June 30, 2023, Payable on 28 September 2023Hansoh Pharmaceutical Group Company Limited announced interim dividend of HKD 0.0707 per share for the six months ended June 30, 2023, payable on 28 September 2023. Record date to be 12 September 2023. Ex-dividend date to be 07 September 2023.Board Change • Sep 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Non-Executive Director Guoqiang Lin was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.공고 • Aug 22Hansoh Pharmaceutical Group Company Limited to Report Q2, 2023 Results on Aug 31, 2023Hansoh Pharmaceutical Group Company Limited announced that they will report Q2, 2023 results on Aug 31, 2023New Risk • Aug 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.Valuation Update With 7 Day Price Move • Aug 04Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to €1.30, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 19x in the Pharmaceuticals industry in Germany. Total loss to shareholders of 60% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €1.86 per share.Buying Opportunity • Jul 31Now 23% undervalued after recent price dropOver the last 90 days, the stock is down 8.8%. The fair value is estimated to be €1.88, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.3% over the last 3 years, while earnings per share has been flat. For the next 3 years, revenue is forecast to grow by 11% per annum. Earnings is also forecast to grow by 12% per annum over the same time period.공고 • Jul 23Hansoh Pharmaceutical Group Company Limited Announces New Drug Application of Ibrexafungerp Tablets Accepted by the National Medical Products AdministrationThe board of directors of Hansoh Pharmaceutical Group Company Limited announced that the New Drug Application of "Ibrexafungerp Tablets" has been accepted by the National Medical Products Administration, and it is intended to be used for the treatment of adult and post-menarchal pediatric females with vulvovaginal candidiasis (VVC). As disclosed in the announcement of the Company dated February 17, 2021, Hansoh (Shanghai) Healthtech Company Limited (Han Sen (Shang Hai) Jian Kang Ke Ji You Xian Gong Si) and Jiangsu Hansoh Pharmaceutical Group Company Limited (Jiang Su Hao Sen Yao Ye Ji Tuan You Xian Gong Si), both wholly-owned subsidiaries of the Company, obtained an exclusive license from SCYNEXIS Inc. to research, develop and commercialize Ibrexafungerp in the People's Republic of China (including Hong Kong, Macau and Taiwan).Buying Opportunity • Jul 14Now 23% undervalued after recent price dropOver the last 90 days, the stock is down 17%. The fair value is estimated to be €1.87, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.3% over the last 3 years, while earnings per share has been flat. For the next 3 years, revenue is forecast to grow by 11% per annum. Earnings is also forecast to grow by 12% per annum over the same time period.공고 • Jun 30Hansoh Pharmaceutical Group Company Limited Announces HS-10518 Capsules A Category 1 Innovative Drug, Has Been Granted A Clinical Trial NoticeThe board of directors of Hansoh Pharmaceutical Group Company Limited announced that "HS-10518 Capsules" (license-in as TU2670, the "Product"), a Category 1 innovative drug, has been granted a clinical trial notice issued by the National Medical Products Administration of the People's Republic of China, and is intended to be used for the management of moderate to severe pain associated with endometriosis and management of heavy menstrual bleeding associated with uterine leiomyomas.Buying Opportunity • Jun 24Now 23% undervalued after recent price dropOver the last 90 days, the stock is down 9.0%. The fair value is estimated to be €1.85, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.3% over the last 3 years, while earnings per share has been flat. For the next 3 years, revenue is forecast to grow by 11% per annum. Earnings is also forecast to grow by 12% per annum over the same time period.공고 • Jun 14Hansoh Pharmaceutical Group Company Limited Provides Update on Clinical Trial Notice of HS-10516 CapsulesThe board of directors of Hansoh Pharmaceutical Group Company Limited announced that "HS-10516 Capsules" (license-in as NKT2152, the "Product"), a Category 1 innovative drug, has been granted a clinical trial notice issued by the National Medical Products Administration of the People's Republic of China, and is intended to be used for the treatment of renal cell carcinoma (RCC).공고 • Jun 06Hansoh (Shanghai) Healthtech Company Limited Obtains an Exclusive License from Biotheus IncHansoh (Shanghai) Healthtech Company Limited obtained an exclusive license from Biotheus Inc. to develop and commercialize PM1080 within China (including Hong Kong, Macau and Taiwan). The board of directors (the "Board") of the Company announced that "HS-20117" (license-in as PM1080), a Category 1 innovative drug developed by the Group under the license from Biotheus, has been granted a clinical trial notice issued by the National Medical Products Administration of the People's Republic of China, and is intended to be used for the treatment of advanced solid tumor.Upcoming Dividend • May 29Upcoming dividend of HK$0.05 per share at 0.8% yieldEligible shareholders must have bought the stock before 05 June 2023. Payment date: 05 July 2023. Payout ratio is a comfortable 20% and this is well supported by cash flows. Trailing yield: 0.8%. Lower than top quartile of German dividend payers (4.7%). Lower than average of industry peers (2.5%).Buying Opportunity • May 13Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 12%. The fair value is estimated to be €1.91, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.3% over the last 3 years, while earnings per share has been flat. For the next 3 years, revenue is forecast to grow by 11% per annum. Earnings is also forecast to grow by 13% per annum over the same time period.공고 • May 06Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of "HS-10506 Tablets"The board of directors (the "Board") of Hansoh Pharmaceutical Group Company Limited announce that "HS-10506 tablets", a Category 1 innovative drug self- developed by Jiangsu Hansoh Pharmaceutical Group Company Limited and Shanghai Hansoh BioMedical Technology Company Limited, both being subsidiaries of the Company, has been granted a clinical trial notice issued by the National Medical Products Administration of the People's Republic of China, and is intended to be used for the treatment of depression and insomnia. The specific indication will be determined after the completion of clinical research.Reported Earnings • Apr 30Full year 2022 earnings released: EPS: CN¥0.44 (vs CN¥0.46 in FY 2021)Full year 2022 results: EPS: CN¥0.44 (down from CN¥0.46 in FY 2021). Revenue: CN¥9.38b (down 5.6% from FY 2021). Net income: CN¥2.58b (down 4.8% from FY 2021). Profit margin: 28% (in line with FY 2021). Post-clinical trial products Approved (during full year): 11 Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings.Board Change • Apr 21Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Non-Executive Director Guoqiang Lin was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Buying Opportunity • Apr 05Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 20%. The fair value is estimated to be €1.88, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.3% over the last 3 years, while earnings per share has been flat. For the next 3 years, revenue is forecast to grow by 12% per annum. Earnings is also forecast to grow by 14% per annum over the same time period.Reported Earnings • Mar 28Full year 2022 earnings releasedFull year 2022 results: Revenue: CN¥9.38b (down 5.6% from FY 2021). Net income: CN¥2.58b (down 4.8% from FY 2021). Profit margin: 28% (in line with FY 2021). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany.공고 • Jan 18Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Approval of Oral Small Molecule 3CL Protease InhibitorThe board of directors (the " Board ") of Hansoh Pharmaceutical Group Company Limited announced that HS-10517 tablets, a Category 1 innovative drug and oral small molecule 3CL protease inhibitor against SARS-CoV-2, for which the Group holds license from Beijing Huayi Health Drug Discovery Institute (also known as the Global Health Drug Discovery Institute, ("GHDDI")), has been granted a clinical trial approval issued by the National Medical Products Administration of the People's Republic of China, and is intended to be used for the treatment of adult patients with mild to moderate SARS-CoV-2 infection. As disclosed in the announcement of the Company dated August 22, 2022, Hansoh (Shanghai) Healthtech Company Limited, a subsidiary of the Company, obtained an exclusive license from GHDDI to develop, manufacture and commercialize the anti-SARS-CoV-2 new drug candidate GDI-4405 series worldwide. ABOUT HS-10517: HS-10517 (belong to GDI-4405 series) is an oral small molecule 3CL protease inhibitor against SARS-CoV-2. HS-10517 exhibits high potent antiviral activity on SARS-CoV-2 delta and omicron variants.공고 • Jan 10Hansoh Pharmaceutical Group Company Limited Announces That " Hs-10390 Tablets " Has Been Granted A Clinical Trial Notice Issued by the National Medical Products Administration of the People's Republic of ChinaThe board of directors of Hansoh Pharmaceutical Group Company Limited announced that " HS-10390 tablets ", a Category 1 innovative drug self-developed by Changzhou Hansoh Pharmaceutical Company Limited and Shanghai Hansoh BioMedical Technology Company Limited both being subsidiaries of the Company, has been granted a clinical trial notice issued by the National Medical Products Administration of the People's Republic of China, and is intended to be used for the treatment of Focal Segmental Glomerulosclerosis and Immunoglobulin A Nephropathy. The specific indication will be determined after the completion of clinical research.Valuation Update With 7 Day Price Move • Dec 30Investor sentiment improved over the past weekAfter last week's 18% share price gain to €1.89, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 16x in the Pharmaceuticals industry in Germany. Total loss to shareholders of 32% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €2.15 per share.공고 • Dec 29Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of "HS-10502 Tablets"The board of directors of Hansoh Pharmaceutical Group Company Limited announced that HS-10502 tablets, a Category 1 innovative drug self-developed by Jiangsu Hansoh Pharmaceutical Group Company Limited has been granted a clinical trial notice issued by the National Medical Products Administration of the People's Republic of China, and is intended to be used for the treatment of advanced solid tumor. The specific indication will be determined after the completion of clinical research.공고 • Dec 04Hansoh Pharmaceutical Group Company Limited Announces European Medicines Agency Accepts Review of EQRx's Marketing Authorization Application for aumolertinibThe board of directors of the Hansoh Pharmaceutical Group Company Limited announced that the European Medicines Agency (EMA) has accepted for review the partner EQRx's marketing authorization application (" MAA ") for aumolertinib, a novel, third-generation epidermal growth factor receptor-tyrosine kinase inhibitor ("EGFR-TKI") being developed and commercialized under the License Agreement, for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer ("NSCLC") with sensitizing EGFR mutations and for the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC. This is the second MAA of aumolertinib filed outside of the People's Republic of China. For details of the first MAA filed with the United Kingdom (U.K.)'s Medicines and Healthcare products Regulatory Agency ("MHRA"), please refer to the announcement of the Company dated June 15, 2022. Aumolertinib is one of the key products. As of the date of this announcement, aumolertinib has two indications approved in China and is currently under review by the MHRA for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with sensitizing EGFR mutations and for the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC. The MAA is primarily supported by data from the Phase III study (the "AENEAS Study") that evaluated aumolertinib in the first-line treatment of EGFR-mutated locally advanced or metastatic NSCLC. Aumolertinib is also currently being evaluated in several other clinical development programs for lung cancer.Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Non-Executive Director Guoqiang Lin was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Valuation Update With 7 Day Price Move • Oct 18Investor sentiment improved over the past weekAfter last week's 15% share price gain to €1.65, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 15x in the Pharmaceuticals industry in Germany. Total loss to shareholders of 41% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €2.91 per share.Valuation Update With 7 Day Price Move • Sep 03Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to €1.75, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 16x in the Pharmaceuticals industry in Germany. Total loss to shareholders of 44% over the past three years.Upcoming Dividend • Sep 01Upcoming dividend of HK$0.05 per shareEligible shareholders must have bought the stock before 08 September 2022. Payment date: 30 September 2022. Payout ratio is a comfortable 25% and this is well supported by cash flows. Trailing yield: 0.7%. Lower than top quartile of German dividend payers (4.7%). Lower than average of industry peers (2.8%).Reported Earnings • Aug 27First half 2022 earnings released: EPS: CN¥0.22 (vs CN¥0.22 in 1H 2021)First half 2022 results: EPS: CN¥0.22 (up from CN¥0.22 in 1H 2021). Revenue: CN¥4.43b (flat on 1H 2021). Net income: CN¥1.30b (flat on 1H 2021). Profit margin: 29% (in line with 1H 2021). Over the next year, revenue is forecast to grow 19%, compared to a 6.6% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.공고 • Aug 27Hansoh Pharmaceutical Group Company Limited Announces Interim Dividend for the Six Months Ended June 30, 2022, Payable on 30 September 2022Hansoh Pharmaceutical Group Company Limited announced interim dividend of HKD 0.05 per share for the six months ended June 30, 2022, payable on 30 September 2022. Record date to be 14 September 2022. Ex-dividend date to be 08 September 2022.공고 • Aug 17Hansoh Pharmaceutical Group Company Limited to Report First Half, 2022 Results on Aug 26, 2022Hansoh Pharmaceutical Group Company Limited announced that they will report first half, 2022 results on Aug 26, 2022Valuation Update With 7 Day Price Move • Aug 06Investor sentiment improved over the past weekAfter last week's 16% share price gain to €2.12, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 15x in the Pharmaceuticals industry in Germany. Total loss to shareholders of 11% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €4.03 per share.Valuation Update With 7 Day Price Move • Jul 22Investor sentiment improved over the past weekAfter last week's 17% share price gain to €2.16, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 14x in the Pharmaceuticals industry in Germany. Total loss to shareholders of 9.2% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €4.06 per share.Valuation Update With 7 Day Price Move • Jun 25Investor sentiment improved over the past weekAfter last week's 16% share price gain to €1.78, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 12x in the Pharmaceuticals industry in Germany. Total loss to shareholders of 27% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €3.54 per share.이익 및 매출 성장 예측DB:3KY - 애널리스트 향후 추정치 및 과거 재무 데이터 (CNY Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/202821,1727,3777,0896,6482012/31/202718,4886,4315,8246,0872212/31/202616,9215,9045,5495,3592212/31/202515,0285,5556,2496,738N/A9/30/202514,1095,1685,3155,762N/A6/30/202513,1894,7814,3824,785N/A3/31/202512,7254,5773,8604,324N/A12/31/202412,2614,3723,3373,862N/A9/30/202412,1794,5433,7374,258N/A6/30/202412,0984,7144,1374,653N/A3/31/202411,1013,9963,4463,885N/A12/31/202310,1043,2782,7543,116N/A9/30/20239,7822,9262,2922,615N/A6/30/20239,4592,5751,8302,114N/A3/31/20239,4212,5792,1402,427N/A12/31/20229,3822,5842,4492,741N/A9/30/20229,6752,6522,6463,004N/A6/30/20229,9682,7202,8423,267N/A3/31/20229,9522,7172,4722,922N/A12/31/20219,9352,7132,1022,577N/A9/30/20219,5242,6751,4152,345N/A6/30/20219,1122,6387292,113N/A3/31/20218,9012,6038402,252N/A12/31/20208,6902,5699512,390N/A9/30/20208,3772,5261,7752,802N/A6/30/20208,0632,4832,6003,213N/A3/31/20208,3732,5202,6663,271N/A12/31/20198,6832,5572,7323,330N/A9/30/20198,6152,357N/A3,092N/A6/30/20198,5482,157N/A2,854N/A3/31/20198,1352,030N/A2,463N/A12/31/20187,7221,903N/A2,072N/A12/31/20176,1861,595N/A1,402N/A12/31/20165,4331,476N/A1,247N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: 3KY 의 연간 예상 수익 증가율(10%)이 saving rate(1.9%)보다 높습니다.수익 vs 시장: 3KY 의 연간 수익(10%)이 German 시장(15.8%)보다 느리게 성장할 것으로 예상됩니다.고성장 수익: 3KY 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.수익 대 시장: 3KY 의 수익(연간 10.9%)이 German 시장(연간 6.7%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: 3KY 의 수익(연간 10.9%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: 3KY의 자본 수익률은 3년 후 15.5%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/26 13:26종가2026/07/24 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Hansoh Pharmaceutical Group Company Limited는 34명의 분석가가 다루고 있습니다. 이 중 22명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Rebecca LiangBernsteinBo LiBofA Global ResearchJin ZhangChina International Capital Corporation Limited31명의 분석가 더 보기
공고 • Jul 10Hansoh Pharmaceutical Group Company Limited Reports Positive Phase III Results For Risvutatug Rezetecan In Small-Cell Lung CancerGSK plc licensor Hansoh Pharmaceutical Group Co. Ltd. announced that ARTEMIS-008, its pivotal phase III trial evaluating risvutatug rezetecan (Ris-Rez) in patients with advanced or relapsed small-cell lung cancer (SCLC), met its primary endpoint of overall survival (OS). In the trial, conducted in patients in China, Ris-Rez demonstrated statistically significant and clinically meaningful improvements in OS compared with the standard of care, topotecan. Consistent benefit was also observed across key secondary endpoints, including progression-free survival. These data will be used by Hansoh Pharma for regulatory submission in China. These are the first positive phase III overall survival data reported for a B7-H3-targeted antibody-drug conjugate (ADC) in any tumour type. The safety profile is consistent with prior Ris-Rez findings, and no new safety signals were identified. GSK holds exclusive global rights to develop Ris-Rez outside mainland China, Hong Kong, Macau and Taiwan. GSK's broad clinical development programme includes studies in lung cancer, prostate cancer and other solid tumours, including the global phase III EMBOLD SCLC-301 trial in relapsed extensive-stage small-cell lung cancer (ES-SCLC) with pivotal data expected next year. Most patients with ES-SCLC relapse after initial therapy and have limited treatment options, poor prognosis and significant treatment burden. B7-H3 is highly expressed in SCLC tumours and the positive results from ARTEMIS-008 add to the growing body of evidence supporting the encouraging clinical activity and manageable safety profile of Ris-Rez in patients with ES-SCLC. Ris-Rez is a novel investigational B7-H3-targeted ADC composed of a fully human anti-B7-H3 monoclonal antibody covalently linked to a topoisomerase inhibitor payload. GSK acquired exclusive worldwide rights (excluding China's mainland, Hong Kong, Macau, and Taiwan) from Hansoh Pharma to progress clinical development and commercialisation of Ris-Rez. Regulatory designations received for Ris-Rez to date include orphan drug designations from the US Food and Drug Administration (FDA) and Japan's Ministry of Health, Labour and Welfare in SCLC and the European Medicines Agency (EMA) in a category of cancer that includes SCLC, called pulmonary neuroendocrine carcinoma; Priority Medicines (PRIME) Designation from the EMA for relapsed or refractory ES-SCLC; and Breakthrough Therapy Designations for relapsed or refractory ES-SCLC and relapsed or refractory osteosarcoma from the US FDA.
Valuation Update With 7 Day Price Move • Jul 03Investor sentiment improves as stock rises 18%After last week's 18% share price gain to €3.69, the stock trades at a forward P/E ratio of 30x. Average forward P/E is 20x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 162% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €6.84 per share.
Upcoming Dividend • Jun 26Upcoming dividend of HK$0.20 per shareEligible shareholders must have bought the stock before 03 July 2026. Payment date: 24 July 2026. Payout ratio is a comfortable 42% and this is well supported by cash flows. Trailing yield: 1.5%. Lower than top quartile of German dividend payers (4.8%). Lower than average of industry peers (2.6%).
New Risk • Jun 07New minor risk - Dividend sustainabilityThe company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 1.5% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company.
공고 • Jun 04Hansoh Pharmaceutical Group Company Limited, Annual General Meeting, Jun 26, 2026Hansoh Pharmaceutical Group Company Limited, Annual General Meeting, Jun 26, 2026, at 10:00 China Standard Time. Location: 50/f, office tower, convention plaza, 1 harbour road, wan chai, Hong Kong
Board Change • May 20Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 3 highly experienced directors. Independent Non-Executive Director Jia Yan was the last director to join the board, commencing their role in 2025. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
공고 • Mar 18Hansoh Pharmaceutical Group Company Limited to Report Fiscal Year 2025 Results on Mar 29, 2026Hansoh Pharmaceutical Group Company Limited announced that they will report fiscal year 2025 results at 9:30 AM, China Standard Time on Mar 29, 2026
공고 • Feb 21Hansoh Pharmaceutical Group Company Limited Announces Approval in the European Union as MonotherapyThe board of directors of Hansoh Pharmaceutical Group Company Limited announced that, on February 12, 2026, Aumolertinib Mesylate Tablets, marketed as Ameile in China and Aumseqa outside China, the Group's innovative drug, has been approved in the European Union as monotherapy for: (i) the first-line treatment of adult patients with advanced non-small cell lung cancer ("NSCLC") whose tumours have epidermal growth factor receptor ("EGFR") exon 19 deletions or exon 21 (L858R) substitution mutations; and (ii) the treatment of adult patients with advanced EGFR T790M mutation-positive NSCLC. The approval by the European Commission (EC) follows the positive opinion of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).
공고 • Jan 08Hansoh Pharmaceutical Group Company Limited Announces Drug Registration Approval of the Fifth Indication of Ameile (Aumolertinib Mesylate Tablets) Was Granted by the National Medical Products AdministrationThe board of directors of Hansoh Pharmaceutical Group Company Limited announced that, the Group's innovative drug Ameile (Aumolertinib Mesylate Tablets) has been granted drug registration approval by the National Medical Products Administration (" NMPA") of China, approving the addition of an indication: Ameile in combination with pemetrexed and platinum-based chemotherapy to be used as the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer ("NSCLC") whose tumors have epidermal growth factor receptor (" EGFR") exon 19 deletions or exon 21 (L858R) mutations. This is the fifth indication of Ameile which has been approved.
공고 • Aug 21Hansoh Pharmaceutical Group Company Limited has filed a Follow-on Equity Offering in the amount of HKD 3.9204 billion.Hansoh Pharmaceutical Group Company Limited has filed a Follow-on Equity Offering in the amount of HKD 3.9204 billion. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 108,000,000 Price\Range: HKD 36.3 Transaction Features: Subsequent Direct Listing
공고 • Aug 07Hansoh Pharmaceutical Group Company Limited to Report First Half, 2025 Results on Aug 18, 2025Hansoh Pharmaceutical Group Company Limited announced that they will report first half, 2025 results on Aug 18, 2025
공고 • Jun 05Hansoh Pharmaceutical Group Company Limited Announces Approval of Aumolertinib Mesilate Tablets by the Medicines and Healthcare Products Regulatory Agency for MarketingThe board of directors of Hansoh Pharmaceutical Group Company Limited announced that, Aumolertinib Mesilate Tablets (trade name in the UK: Aumseqa®?), the Group's innovative drug, has been approved by the Medicines and Healthcare Products Regulatory Agency ("MHRA") in the UK for marketing. Aumseqa®? as monotherapy is indicated for: the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer ("NSCLC") with activating epidermal growth factor receptor (" EGFR") mutations, and the treatment of adult patients with locally Advanced or metastatic EGFR T790M mutation-positive NSCLC.
공고 • May 31Hansoh Pharmaceutical Group Company Limited Announces the Third Biologics License Application of Xin Yue (Inebilizumab Injection) Has Been Accepted by the National Medical Products AdministrationThe board of directors of Hansoh Pharmaceutical Group Company Limited announced that, on May 29, 2025, the third biologics license application ("BLA") of XINYUE (Xin Yue ®?) (Inebilizumab Injection) (the "Product") has been accepted by the National Medical Products Administration (the "NMPA"), which is for the treatment of generalized myasthenia gravis (gMG) in adult patients.
공고 • May 30+ 1 more updateHansoh Pharmaceutical Group Company Limited Obtains Clinical Trial Approval Issued by the National Medical Products AdministrationThe board of directors of Hansoh Pharmaceutical Group Company Limited announce that, HS-10542 capsules, a Category 1 innovative drug self-developed by the Group, has obtained the Clinical Trial Approval issued by the National Medical Products Administration (NMPA) of China, which is intended to be investigated in clinical trials for paroxysmal nocturnal hemoglobinuria (PNH), and immunoglobulin A nephropathy (IgAN).
공고 • May 29+ 1 more updateHansoh Pharmaceutical Group Company Limited, Annual General Meeting, Jun 20, 2025Hansoh Pharmaceutical Group Company Limited, Annual General Meeting, Jun 20, 2025, at 10:00 China Standard Time. Location: 50/f, office tower, convention plaza, 1 harbour road, wan chai, Hong Kong
공고 • Apr 17National Medical Products Administration Grants Breakthrough-Therapy-Designated Drug for B7-H3-Targeted Antibody-Drug Conjugate Hs-20093 for InjectionHansoh Pharmaceutical Group Company Limited announced that, on April 17, 2025, the Group's self-developed B7-H3-targeted antibody-drug conjugate ("ADC") HS-20093 for injection has obtained approval to be included as Breakthrough-Therapy-Designated Drug by the National Medical Products Administration (" NMPA") of China, with the proposed indication for locally advanced or metastatic non-squamous non-small cell lung cancer without driver mutations, progressed or recurred following platinum-based chemotherapy.
공고 • Apr 15Hansoh Pharmaceutical Group Company Limited Obtains Clinical Trial Approval for Hs-10529 TabletsThe board of directors of Hansoh Pharmaceutical Group Company Limited announced that, HS-10529 tablets, a Small Molecule Category I Innovative Drug targeting KRAS G12D self-developed by the Group, has obtained the Clinical Trial Approval issued by the National Medical Products Administration (NMPA) of China, which is intended to be investigated in clinical trials for advanced solid tumors (pancreatic cancer, colorectal cancer, non-small cell lung cancer, etc.) with KRAS G12D mutations.
공고 • Apr 07+ 1 more updateHansoh Pharmaceutical Group Company Limited Obtains Clinical Trial Approval for HS-20108 for InjectionThe board of directors of Hansoh Pharmaceutical Group Company Limited announced that, innovative drug HS-20108 for injection, self-developed by the Group, has obtained the Clinical Trial Approval issued by the National Medical Products Administration (NMPA) of China recently, which is intended to be investigated in clinical trials for advanced solid tumors such as small cell lung cancer and neuroendocrine tumors.
공고 • Mar 21Hansoh Pharmaceutical Group Company Limited Proposes Final Ordinary Dividend for the Year Ended December 31, 2024, Payable on July 25, 2025Hansoh Pharmaceutical Group Company Limited proposed final ordinary dividend of HKD 0.1353 per share for the year ended December 31, 2024. Ex-dividend date: July 3, 2025. Record date: July 9, 2025. Payment date: July 25, 2025.
공고 • Mar 20TiumBio Co., Ltd.'s Partner Hansoh Pharma Expands Indications for Merigolix (HS-10518) with Initiation of ART (Assisted Reproductive Technology) DevelopmentTiumBio Co. Ltd. announced that its partner, Hansoh Pharma, has expanded the clinical indications of merigolix (Hansoh's code: HS-10518), an oral gonadotropin-releasing hormone receptor antagonist. Orally administered merigolix may be important in the control of premature endogenous LH surge and in reducing the cycle cancellation rate, with an improvement of pregnancy rate per cycle. Currently, in COS regimens, gonadotropin-re releasing hormone (GnRH) products are only available in injectable form, which caused the pain and relatively high cost. Meanwhile, merigolix is an oral GnRH receptor antagonist being developed for the treatment of endometriosis,uterine fibroids, and ART. TiumBio entered into a licensing agreement with Hansoh Pharma for merigolix for up to $170 million plus tiered royalties upon net sales. Under the terms of the agreement, Hansoh Pharma obtained exclusive rights to develop and commercialize merigolix in Greater China.
공고 • Mar 10Hansoh Pharmaceutical Group Company Limited to Report Fiscal Year 2024 Results on Mar 21, 2025Hansoh Pharmaceutical Group Company Limited announced that they will report fiscal year 2024 results on Mar 21, 2025
공고 • Mar 05Hansoh Pharmaceutical Group Company Limited Announces Acceptance of Second Biologics License Application by the National Medical Products AdministrationThe board of directors of Hansoh Pharmaceutical Group Company Limited announced that, on March 4, 2025, the second Biologics License Application (BLA) of XINYUE (Inebilizumab Injection) has been accepted by the National Medical Products Administration (the "NMPA"), which is for the treatment of immunoglobulin G4-related disease (IgG4-RD). On February 8, 2025, this indication has been included in the Priority Review and Approval Procedure by the NMPA. Inebilizumab is a targeted CD19 B cell-depleting antibody. On May 24, 2019, the Group entered into a license agreement with Viela Bio (Viela Bio was acquired by Horizon Therapeutics in 2021, which was acquired by Amgen in 2023), and has been granted an exclusive license to develop and commercialize the Product in China's mainland, Hong Kong and Macao. On March 14, 2022, the Product was approved to be launched in China by NMPA for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive. In January 2023, the Product was included in the National Reimbursement Drug List for the first time, and this inclusion was successfully renewed in November 2024.
공고 • Feb 25+ 1 more updateNational Medical Products Administration Grants Breakthrough-Therapy-Designated Drug for B7-H3-T Targeted Antibody-Drug Conjugate HS-20093 for Osteosarcoma of Hansoh Pharmaceutical Group Company LimitedThe board of directors of Hansoh Pharmaceutical Group Company Limited announced that on February 25, 2025, the Group's self-developed B7-H3-targeted antibody-drug conjugate ("ADC") HS-20093 for injection has obtained approval to be included as Breakthrough-Therapy-Designated Drug by the National Medical Products Administration of China, with the proposed indication for the treatment of patients with osteosarcoma who have progressed on at least two prior lines of therapy. HS-20093 is an investigational B7-H3-targeted ADC composed of a fully human anti-B7-H3 monoclonal antibody covalently linked to topoisomerase inhibitor (TOPOi) payload and being developed for the treatment of lung cancer, sarcoma, head and neck cancers and other solid tumors in multiple clinical trials in China, with the highest research stage being Phase III clinical trials. On November 1, 2024, the NMPA listed HS-20093 as a Breakthrough-Therapy-Designated Drug, with the indication being extensive-stage small-cell lung cancer (ES-SCLC) developed after standard first-line treatment (platinum doublet chemotherapy combined with immuno-therapy).
공고 • Feb 10Hansoh Pharmaceutical Group Company Limited Announces New Indication of Xin Yue (Inebilizumab Injection) Included in Priority Review and Approval Procedure by the National Medical Products AdministrationThe board of directors of Hansoh Pharmaceutical Group Company Limited announced that, on February 8, 2025, based on the positive results from the global pivotal Phase III MITIGATE trial on XINYUE (Xin Yue ®?) (Inebilizumab Injection) (the Product), the new indication of the treatment of immunoglobulin G4-related disease (IgG4-RD) of the Product has been included in the Priority Review and Approval Procedure by the National Medical Products Administration (the NMPA).
공고 • Jan 24Hansoh Pharmaceutical Group Company Limited Announces Changes to Company SecretaryThe board of directors of Hansoh Pharmaceutical Group Company Limited announced that, with effect from January 24, 2025, due to personal work arrangement, Ms. Tam Sze Wai Sara has tendered her resignation as a joint company secretary of the Company and ceased to be an authorized representative of the Company under Rule 3.05 of the Rule Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules") and the process agent of the Company in Hong Kong for the purpose of accepting service of process and notices on its behalf as required under Rule 19.05(2) of the Listing Rules and Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) (the "Process Agent"). Following the resignation of Ms. Tam, the Board announces that Ms. Wong Yuen Ki (" Ms. Wong") has been appointed as the joint company secretary with effect from January 24, 2025. Ms. Wong is a senior manager of corporate services of Tricor Services Limited. Ms. Wong possesses more than 10 years of experience in the company secretarial field. Ms. Wong is a Chartered Secretary, a Chartered Governance Professional and an associate of both The Hong Kong Chartered Governance Institute and The Chartered Governance Institute. Ms. Wong holds a degree of Bachelor of Business Administration in Corporate Administration and degree of Master of Corporate Governance from Hong Kong Metropolitan University. Ms. Wong possesses the academic or professional qualifications of a company secretary as required under Rule 3.28 of the Listing Rules. With effect from January 24, 2025, the joint company secretaries of the Company are Ms. Zhong Shengli and Ms. Wong.
Board Change • Dec 30Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 3 highly experienced directors. Independent Non-Executive Director Guoqiang Lin was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
공고 • Nov 27Hansoh Pharmaceutical Group Company Limited Announces the Fifth New Drug Application of Ameile (Aumolertinib Mesilate Tablets) Was Accepted by the National Medical Products AdministrationHansoh Pharmaceutical Group Company Limited announced that, the fifth New Drug Application ("NDA") of the Group's innovative drug Ameile (A Mei Le ®?) (Aumolertinib Mesilate Tablets) has been accepted by the National Medical Products Administration of China ("NMPA"). The indication is that Ameile in combination with pemetrexed and platinum-based chemotherapy to be used as the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer ("NSCLC") whose tumors have epidermal growth factor receptor (" EGFR") exon 19 deletions or exon 21 (L858R) mutations. . Ameile (Aumolertinib Mesilate Tablets) is the first innovative third-generation EGFR-TKI drug wholly developed in China. In March 2020, Ameile obtained approval for the treatment of patients with locally advanced or metastatic NSCLC with T790M mutation, who have progressed on or after EGFR-TKI therapy. In December 2021, Ameile obtained approval to be used as the first-line treatment for adult patients with locally advanced or metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitute mutation positive. In July 2024, the NDA of Ameile for adjuvant therapy after tumor resection in patients with NSCLC whose tumors have EGFR exon 19 deletions or exon 21 (L858R) mutations was accepted by the NMPA. In August 2024, the NDA of Ameile for the treatment in patients with locally advanced, unresectable, EGFR exon 19 deletions or exon 21 (L858R) mutations, NSCLC without progression following definitive platinum-based chemoradiotherapy was accepted by the NMPA.
Valuation Update With 7 Day Price Move • Nov 01Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to €2.02, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 14x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 20% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €3.33 per share.
공고 • Nov 01Hansoh Pharmaceutical Group Company Limited Announces the NMPA Has Granted Breakthrough-Therapy-Designated Drug for B7-H3-Targeted Antibody-Drug Conjugate HS-20093The board of directors of Hansoh Pharmaceutical Group Company Limited announced that on November 1, 2024, the Group's self-developed B7-H3-targeted antibody-drug conjugate (‘ADC’) HS-20093 for injection has obtained approval to be included as Breakthrough-Therapy-Designated Drug by the National Medical Products Administration (‘NMPA’) of China, with the proposed indication being extensive stage small cell lung cancer (‘ES-SCLC’) developed after standard first-line treatment (platinum doublet chemotherapy combined with immuno-therapy).
공고 • Oct 22Hansoh Pharmaceutical Group Company Limited Announces Phase III Registrational Trial AENEAS2 Evaluating Ameile in Combination with Chemotherapy for Patients with Locally Advanced or Metastatic EGFR-Mutated NSCLCThe board of directors of Hansoh Pharmaceutical Group Company Limited announced that Phase III registrational trial AENEAS2 evaluating Ameile in combination with chemotherapy as first line therapy for patients with locally advanced (Stage IIIB~IIIC) or metastatic (Stage IV) epidermal growth factor receptor mutated non-small cell lung cancer met its primary endpoint of progression-free survival .AMEILE combined with chemotherapy demonstrated statistically significant and clinically meaningful improvement in PFS in patients with EGFR mutated advanced lung cancer. Detailed results of the study will be presented at upcoming medical conference and will be submitted to regulatory authority. Ameile (Aumolertinib Mesilate Tablets) is the first innovative third-generation EGFR-TKI drug wholly developed in China. In March 2020, Ameile obtained approval for the treatment of patients with locally advanced or metastatic NSCLC with T790M mutation, who have progressed on or after EGFR-TKI therapy, and was also successfully renewed in the 2022 National Reimbursement Drug List ("NRDL") in January 2023. In December 2021, Ameile obtained approval to be used as the first-line treatment for adult patients with locally advanced or metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitute mutation positive, and has been included in the 2022 NRDL in January 2023. In July 2024, the New Drug Application ("NDA") of Ameile for adjuvant therapy after tumor resection in patients with NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations was accepted by the National Medical Products Administration (" NMPA "). In August 2024, the NDA of Ameile for the treatment in patients with locally advanced, unresectable, EGFR exon 19 deletions or exon 21 (L858R) mutations, NSCLC without progression following definitive platinum-based chemoradiotherapy was accepted by the NMPA.
New Risk • Oct 09New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 2.5% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 2.5% per year for the foreseeable future. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (10% average weekly change). Significant insider selling over the past 3 months (€69m sold).
Valuation Update With 7 Day Price Move • Oct 03Investor sentiment improves as stock rises 22%After last week's 22% share price gain to €2.66, the stock trades at a forward P/E ratio of 29x. Average forward P/E is 14x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 42% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €3.63 per share.
Reported Earnings • Sep 27First half 2024 earnings released: EPS: CN¥0.46 (vs CN¥0.22 in 1H 2023)First half 2024 results: EPS: CN¥0.46 (up from CN¥0.22 in 1H 2023). Revenue: CN¥6.51b (up 44% from 1H 2023). Net income: CN¥2.73b (up 112% from 1H 2023). Profit margin: 42% (up from 29% in 1H 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth.
Upcoming Dividend • Sep 13Upcoming dividend of HK$0.20 per shareEligible shareholders must have bought the stock before 20 September 2024. Payment date: 30 October 2024. Payout ratio is a comfortable 40% and this is well supported by cash flows. Trailing yield: 2.1%. Lower than top quartile of German dividend payers (4.9%). Higher than average of industry peers (1.1%).
Declared Dividend • Aug 29First half dividend of HK$0.20 announcedShareholders will receive a dividend of HK$0.20. Ex-date: 20th September 2024 Payment date: 30th October 2024 Dividend yield will be 9.3%, which is higher than the industry average of 2.4%. Sustainability & Growth Dividend is covered by both earnings (40% earnings payout ratio) and cash flows (79% cash payout ratio). The dividend has increased by an average of 78% per year over the past 3 years and payments have been stable during that time. EPS is expected to decline by 8.3% over the next 3 years. However, it would need to fall by 56% to increase the payout ratio to a potentially unsustainable range.
Reported Earnings • Aug 28First half 2024 earnings released: EPS: CN¥0.46 (vs CN¥0.22 in 1H 2023)First half 2024 results: EPS: CN¥0.46 (up from CN¥0.22 in 1H 2023). Revenue: CN¥6.51b (up 44% from 1H 2023). Net income: CN¥2.73b (up 112% from 1H 2023). Profit margin: 42% (up from 29% in 1H 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 7.9% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.
공고 • Aug 27Hansoh Pharmaceutical Group Company Limited Announces an Interim Dividend for the Six Months Ended June 30, 2024, Payable on 30 October 2024Hansoh Pharmaceutical Group Company Limited announced an interim dividend of HKD 0.201 per share for the six months ended June 30, 2024. Ex-dividend date is 20 September 2024. Record date is 25 September 2024. Payment date is 30 October 2024.
공고 • Aug 15Hansoh Pharmaceutical Group Company Limited to Report First Half, 2024 Results on Aug 27, 2024Hansoh Pharmaceutical Group Company Limited announced that they will report first half, 2024 results on Aug 27, 2024
공고 • Jul 20Hansoh Pharmaceutical Group Company Limited Announces New Drug Application of Ammeile for the Adjuvant Treatment of Egfr Mutation-Positive Non-Small Cell Lung Cancer Accepted by the National Medical Products Administration of the People's Republic of ChinaThe board of directors of Hansoh Pharmaceutical Group Company Limited announced that the New Drug Application of "Ameile" (A Mei Le ®?) for adjuvant therapy after tumor resection in patients with non-small cell lung cancer ("NSCLC") whose tumors have epidermal growth factor receptor ("EGFR") exon 19 deletions or exon 21 L858R mutations, was accepted by the National Medical Products Administration of the People's Republic of China. Ameile is a category 1 innovative drug developed by Jiangsu Hansoh Pharmaceutical Group Co. Ltd. ("J Jiang Su Hao Sen Yao Ye Ji Tuan You Xian Gong Si"), a subsidiary of the Company. The said application will be the third indication of Ameile.
Buy Or Sell Opportunity • Jul 02Now 27% undervaluedThe stock has been flat over the last 90 days, currently trading at €1.86. The fair value is estimated to be €2.55, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 2.9% over the last 3 years. Earnings per share has grown by 3.9%. For the next 3 years, revenue is forecast to grow by 9.1% per annum. Earnings are also forecast to grow by 8.6% per annum over the same time period.
Buy Or Sell Opportunity • Jun 19Now 21% undervaluedOver the last 90 days, the stock has risen 15% to €1.97. The fair value is estimated to be €2.48, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 2.9% over the last 3 years. Earnings per share has grown by 3.9%. For the next 3 years, revenue is forecast to grow by 9.1% per annum. Earnings are also forecast to grow by 8.6% per annum over the same time period.
Upcoming Dividend • Jun 12Upcoming dividend of HK$0.14 per shareEligible shareholders must have bought the stock before 19 June 2024. Payment date: 17 July 2024. Payout ratio is a comfortable 35% and this is well supported by cash flows. Trailing yield: 1.6%. Lower than top quartile of German dividend payers (4.6%). Lower than average of industry peers (2.2%).
공고 • May 01Hansoh Pharmaceutical Group Company Limited, Annual General Meeting, Jun 13, 2024Hansoh Pharmaceutical Group Company Limited, Annual General Meeting, Jun 13, 2024, at 10:00 China Standard Time. Location: 10/F United Centre, 95 Queensway Admiralty Hong Kong Agenda: To receive and adopt the audited consolidated financial statements of the Company and the reports of the directors and auditors for the year ended December 31, 2023; to approve the payment of a final dividend for the year ended December 31, 2023; to re-elect Dr. Lyu Aifeng as executive director; to re-elect Mr. Lin Guoqiang as independent non-executive director; to authorize the board of directors to fix the respective directors' remuneration; to re-appoint Ernst & Young as auditors and to authorize the board of directors to fix their remuneration; and to transact other business.
Reported Earnings • Apr 30Full year 2023 earnings released: EPS: CN¥0.55 (vs CN¥0.44 in FY 2022)Full year 2023 results: EPS: CN¥0.55 (up from CN¥0.44 in FY 2022). Revenue: CN¥10.1b (up 7.7% from FY 2022). Net income: CN¥3.28b (up 27% from FY 2022). Profit margin: 32% (up from 28% in FY 2022). Post-clinical trial products Approved (during full year): 6 Revenue is forecast to grow 8.9% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.
공고 • Apr 30Hansoh Pharmaceutical Group Company Limited Announces Executive Changes, Effective April 29, 2024Hansoh Pharmaceutical Group Company Limited announced that, with effect from April 29, 2024, Ms. Li Yan Wing Rita (Ms. Li) has tendered her resignation as a joint company secretary of the company and ceased to be an authorized representative of the company (the Authorized Representative) under Rule 3.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the process agent of the company in Hong Kong for the purpose of accepting service of process and notices on its behalf as required under Rule 19.05(2) of the Listing Rules and Part 16 of the Companies Ordinance. Following the resignation of Ms. Li, the board announced that Ms. Tam Sze Wai Sara (Ms. Tam) has been appointed as a joint company secretary with effect from April 29, 2024. Ms. Tam is currently a manager of Corporate Services of Tricor Services Limited. She has over 10 years of experience in the corporate secretarial field and has been providing professional corporate services to Hong Kong listed companies as well as multinational, private and offshore companies. Ms. Tam is a Chartered Secretary, a Chartered Governance Professional and an associate of both The Hong Kong Chartered Governance Institute and The Chartered Governance Institute. Following the resignation of Ms. Li, she has also ceased to be an Authorized Representative and the Process Agent with effect from April 29, 2024. The Board announced that Ms. Tam, the newly appointed joint company secretary, has been appointed as an Authorized Representative and the Process Agent with effect from April 29, 2024.
Buy Or Sell Opportunity • Apr 29Now 21% undervaluedOver the last 90 days, the stock has risen 39% to €2.00. The fair value is estimated to be €2.53, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 2.9% over the last 3 years. Earnings per share has grown by 3.9%. For the next 3 years, revenue is forecast to grow by 8.9% per annum. Earnings are also forecast to grow by 8.7% per annum over the same time period.
공고 • Apr 03Hansoh Pharmaceutical Group Company Limited, Jiangsu Hansoh Pharmaceutical Group Company Limited and Shanghai Hansoh Biomedical Technology Company Limited Receives Grant of A Clinical Trial Notice Issued by the National Medical Products Administration of the People's Republic of China to Be Used for the Treatment of Advanced Non-Small Cell Lung CancerThe board of directors of Hansoh Pharmaceutical Group Company Limited announced that "HS- 10504 tablets", a Category 1 innovative drug self-developed by Jiangsu Hansoh Pharmaceutical Group Company Limited and Shanghai Hansoh Biomedical Technology Company Limited, both being subsidiaries of the Company, has been granted a clinical trial notice issued by the National Medical Products Administration of the People's Republic of China, and is intended to be used for the treatment of advanced non-small cell lung cancer. The specific indication will be determined after the completion of clinical research.
New Risk • Mar 28New minor risk - Dividend sustainabilityThe company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 1.8% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (10% average weekly change). Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past.
Reported Earnings • Mar 27Full year 2023 earnings released: EPS: CN¥0.55 (vs CN¥0.44 in FY 2022)Full year 2023 results: EPS: CN¥0.55 (up from CN¥0.44 in FY 2022). Revenue: CN¥10.1b (up 7.7% from FY 2022). Net income: CN¥3.28b (up 27% from FY 2022). Profit margin: 32% (up from 28% in FY 2022). Revenue is forecast to grow 9.9% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.
공고 • Mar 15Hansoh Pharmaceutical Group Company Limited to Report Fiscal Year 2023 Results on Mar 26, 2024Hansoh Pharmaceutical Group Company Limited announced that they will report fiscal year 2023 results on Mar 26, 2024
Valuation Update With 7 Day Price Move • Feb 17Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €1.59, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 16x in the Pharmaceuticals industry in Germany. Total loss to shareholders of 62% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €2.29 per share.
Board Change • Jan 25Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 2 highly experienced directors. Independent Non-Executive Director Guoqiang Lin was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
공고 • Jan 17Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of HS-10509 TabletsThe board of directors of Hansoh Pharmaceutical Group Company Limited announced that "HS-10509 tablets", a Category 1 innovative drug self-developed by Jiangsu Hansoh Pharmaceutical Group Company Limited and Shanghai Hansoh Biomedical Technology Company Limited, both being subsidiaries of the Company, has been granted a clinical trial notice issued by the National Medical Products Administration of the People's Republic of China, and is intended to be used for the treatment of schizophrenia. The specific indication will be determined after the completion of clinical research.
공고 • Nov 11Shanghai Hansoh Biomedical Technology Company Limited and Jiangsu Hansoh Pharmaceutical Group Company Limited Receives Clinical Trial NoticeThe board of directors of Hansoh Pharmaceutical Group Company Limited announced that "HS-10511 tablets", a Category 1 innovative drug self-developed by Shanghai Hansoh Biomedical Technology Company Limited ("Shang Hai Han Sen Sheng Wu Yi Yao Ke Ji You Xian Gong Si") and Jiangsu Hansoh Pharmaceutical Group Company Limited ("Jiang Su Hao Sen Yao Ye Ji Tuan You Xian Gong Si"), both being subsidiaries of the Company, has been granted a clinical trial notice issued by the National Medical Products Administration of the People's Republic of China, and is intended to be used for the treatment of hypertrophic cardiomyopathy (HCM). The specific indication will be determined after the completion of clinical research.
Valuation Update With 7 Day Price Move • Oct 28Investor sentiment improves as stock rises 24%After last week's 24% share price gain to €1.70, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 16x in the Pharmaceuticals industry in Germany. Total loss to shareholders of 52% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €1.85 per share.
New Risk • Oct 25New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 8.6% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. This is currently the only risk that has been identified for the company.
공고 • Oct 20Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of Hs-20106 InjectionsHansoh Pharmaceutical Group Company Limited announced that "HS-20106 Injections" (the "Product"), a Category 1 therapeutic biological product has been granted a clinical trial notice issued by the National Medical Products Administration of the People's Republic of China. The specific indication will be determined after the completion of clinical research.
Reported Earnings • Oct 01First half 2023 earnings released: EPS: CN¥0.22 (vs CN¥0.22 in 1H 2022)First half 2023 results: EPS: CN¥0.22 (down from CN¥0.22 in 1H 2022). Revenue: CN¥4.51b (up 1.7% from 1H 2022). Net income: CN¥1.29b (flat on 1H 2022). Profit margin: 29% (in line with 1H 2022). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 3.5% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings.
공고 • Sep 26Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of "HS-20105"The board of directors of Hansoh Pharmaceutical Group Company Limited announced that "HS-20105", a Category 1 therapeutic biological product self-developed by Shanghai Hansoh Biomedical Technology Company Limited ("Shang Hai Han Sen Sheng Wu Yi Yao Ke Ji You Xian Gong Si") and Changzhou Hansoh Pharmaceutical Company Limited ("Ch Chang Zhou Heng Bang Yao Ye You Xian Gong Si"), both being subsidiaries of the Company, has been granted a clinical trial notice issued by the National Medical Products Administration of the People's Republic of China, and is intended to be used for the treatment of advanced solid tumors. The specific indication will be determined after the completion of clinical research.
공고 • Sep 02Hansoh Pharmaceutical Group Company Limited Announces Interim Dividend for the Six Months Ended June 30, 2023, Payable on 28 September 2023Hansoh Pharmaceutical Group Company Limited announced interim dividend of HKD 0.0707 per share for the six months ended June 30, 2023, payable on 28 September 2023. Record date to be 12 September 2023. Ex-dividend date to be 07 September 2023.
Board Change • Sep 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Non-Executive Director Guoqiang Lin was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
공고 • Aug 22Hansoh Pharmaceutical Group Company Limited to Report Q2, 2023 Results on Aug 31, 2023Hansoh Pharmaceutical Group Company Limited announced that they will report Q2, 2023 results on Aug 31, 2023
New Risk • Aug 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
Valuation Update With 7 Day Price Move • Aug 04Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to €1.30, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 19x in the Pharmaceuticals industry in Germany. Total loss to shareholders of 60% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €1.86 per share.
Buying Opportunity • Jul 31Now 23% undervalued after recent price dropOver the last 90 days, the stock is down 8.8%. The fair value is estimated to be €1.88, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.3% over the last 3 years, while earnings per share has been flat. For the next 3 years, revenue is forecast to grow by 11% per annum. Earnings is also forecast to grow by 12% per annum over the same time period.
공고 • Jul 23Hansoh Pharmaceutical Group Company Limited Announces New Drug Application of Ibrexafungerp Tablets Accepted by the National Medical Products AdministrationThe board of directors of Hansoh Pharmaceutical Group Company Limited announced that the New Drug Application of "Ibrexafungerp Tablets" has been accepted by the National Medical Products Administration, and it is intended to be used for the treatment of adult and post-menarchal pediatric females with vulvovaginal candidiasis (VVC). As disclosed in the announcement of the Company dated February 17, 2021, Hansoh (Shanghai) Healthtech Company Limited (Han Sen (Shang Hai) Jian Kang Ke Ji You Xian Gong Si) and Jiangsu Hansoh Pharmaceutical Group Company Limited (Jiang Su Hao Sen Yao Ye Ji Tuan You Xian Gong Si), both wholly-owned subsidiaries of the Company, obtained an exclusive license from SCYNEXIS Inc. to research, develop and commercialize Ibrexafungerp in the People's Republic of China (including Hong Kong, Macau and Taiwan).
Buying Opportunity • Jul 14Now 23% undervalued after recent price dropOver the last 90 days, the stock is down 17%. The fair value is estimated to be €1.87, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.3% over the last 3 years, while earnings per share has been flat. For the next 3 years, revenue is forecast to grow by 11% per annum. Earnings is also forecast to grow by 12% per annum over the same time period.
공고 • Jun 30Hansoh Pharmaceutical Group Company Limited Announces HS-10518 Capsules A Category 1 Innovative Drug, Has Been Granted A Clinical Trial NoticeThe board of directors of Hansoh Pharmaceutical Group Company Limited announced that "HS-10518 Capsules" (license-in as TU2670, the "Product"), a Category 1 innovative drug, has been granted a clinical trial notice issued by the National Medical Products Administration of the People's Republic of China, and is intended to be used for the management of moderate to severe pain associated with endometriosis and management of heavy menstrual bleeding associated with uterine leiomyomas.
Buying Opportunity • Jun 24Now 23% undervalued after recent price dropOver the last 90 days, the stock is down 9.0%. The fair value is estimated to be €1.85, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.3% over the last 3 years, while earnings per share has been flat. For the next 3 years, revenue is forecast to grow by 11% per annum. Earnings is also forecast to grow by 12% per annum over the same time period.
공고 • Jun 14Hansoh Pharmaceutical Group Company Limited Provides Update on Clinical Trial Notice of HS-10516 CapsulesThe board of directors of Hansoh Pharmaceutical Group Company Limited announced that "HS-10516 Capsules" (license-in as NKT2152, the "Product"), a Category 1 innovative drug, has been granted a clinical trial notice issued by the National Medical Products Administration of the People's Republic of China, and is intended to be used for the treatment of renal cell carcinoma (RCC).
공고 • Jun 06Hansoh (Shanghai) Healthtech Company Limited Obtains an Exclusive License from Biotheus IncHansoh (Shanghai) Healthtech Company Limited obtained an exclusive license from Biotheus Inc. to develop and commercialize PM1080 within China (including Hong Kong, Macau and Taiwan). The board of directors (the "Board") of the Company announced that "HS-20117" (license-in as PM1080), a Category 1 innovative drug developed by the Group under the license from Biotheus, has been granted a clinical trial notice issued by the National Medical Products Administration of the People's Republic of China, and is intended to be used for the treatment of advanced solid tumor.
Upcoming Dividend • May 29Upcoming dividend of HK$0.05 per share at 0.8% yieldEligible shareholders must have bought the stock before 05 June 2023. Payment date: 05 July 2023. Payout ratio is a comfortable 20% and this is well supported by cash flows. Trailing yield: 0.8%. Lower than top quartile of German dividend payers (4.7%). Lower than average of industry peers (2.5%).
Buying Opportunity • May 13Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 12%. The fair value is estimated to be €1.91, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.3% over the last 3 years, while earnings per share has been flat. For the next 3 years, revenue is forecast to grow by 11% per annum. Earnings is also forecast to grow by 13% per annum over the same time period.
공고 • May 06Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of "HS-10506 Tablets"The board of directors (the "Board") of Hansoh Pharmaceutical Group Company Limited announce that "HS-10506 tablets", a Category 1 innovative drug self- developed by Jiangsu Hansoh Pharmaceutical Group Company Limited and Shanghai Hansoh BioMedical Technology Company Limited, both being subsidiaries of the Company, has been granted a clinical trial notice issued by the National Medical Products Administration of the People's Republic of China, and is intended to be used for the treatment of depression and insomnia. The specific indication will be determined after the completion of clinical research.
Reported Earnings • Apr 30Full year 2022 earnings released: EPS: CN¥0.44 (vs CN¥0.46 in FY 2021)Full year 2022 results: EPS: CN¥0.44 (down from CN¥0.46 in FY 2021). Revenue: CN¥9.38b (down 5.6% from FY 2021). Net income: CN¥2.58b (down 4.8% from FY 2021). Profit margin: 28% (in line with FY 2021). Post-clinical trial products Approved (during full year): 11 Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings.
Board Change • Apr 21Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Non-Executive Director Guoqiang Lin was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Buying Opportunity • Apr 05Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 20%. The fair value is estimated to be €1.88, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.3% over the last 3 years, while earnings per share has been flat. For the next 3 years, revenue is forecast to grow by 12% per annum. Earnings is also forecast to grow by 14% per annum over the same time period.
Reported Earnings • Mar 28Full year 2022 earnings releasedFull year 2022 results: Revenue: CN¥9.38b (down 5.6% from FY 2021). Net income: CN¥2.58b (down 4.8% from FY 2021). Profit margin: 28% (in line with FY 2021). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany.
공고 • Jan 18Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Approval of Oral Small Molecule 3CL Protease InhibitorThe board of directors (the " Board ") of Hansoh Pharmaceutical Group Company Limited announced that HS-10517 tablets, a Category 1 innovative drug and oral small molecule 3CL protease inhibitor against SARS-CoV-2, for which the Group holds license from Beijing Huayi Health Drug Discovery Institute (also known as the Global Health Drug Discovery Institute, ("GHDDI")), has been granted a clinical trial approval issued by the National Medical Products Administration of the People's Republic of China, and is intended to be used for the treatment of adult patients with mild to moderate SARS-CoV-2 infection. As disclosed in the announcement of the Company dated August 22, 2022, Hansoh (Shanghai) Healthtech Company Limited, a subsidiary of the Company, obtained an exclusive license from GHDDI to develop, manufacture and commercialize the anti-SARS-CoV-2 new drug candidate GDI-4405 series worldwide. ABOUT HS-10517: HS-10517 (belong to GDI-4405 series) is an oral small molecule 3CL protease inhibitor against SARS-CoV-2. HS-10517 exhibits high potent antiviral activity on SARS-CoV-2 delta and omicron variants.
공고 • Jan 10Hansoh Pharmaceutical Group Company Limited Announces That " Hs-10390 Tablets " Has Been Granted A Clinical Trial Notice Issued by the National Medical Products Administration of the People's Republic of ChinaThe board of directors of Hansoh Pharmaceutical Group Company Limited announced that " HS-10390 tablets ", a Category 1 innovative drug self-developed by Changzhou Hansoh Pharmaceutical Company Limited and Shanghai Hansoh BioMedical Technology Company Limited both being subsidiaries of the Company, has been granted a clinical trial notice issued by the National Medical Products Administration of the People's Republic of China, and is intended to be used for the treatment of Focal Segmental Glomerulosclerosis and Immunoglobulin A Nephropathy. The specific indication will be determined after the completion of clinical research.
Valuation Update With 7 Day Price Move • Dec 30Investor sentiment improved over the past weekAfter last week's 18% share price gain to €1.89, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 16x in the Pharmaceuticals industry in Germany. Total loss to shareholders of 32% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €2.15 per share.
공고 • Dec 29Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of "HS-10502 Tablets"The board of directors of Hansoh Pharmaceutical Group Company Limited announced that HS-10502 tablets, a Category 1 innovative drug self-developed by Jiangsu Hansoh Pharmaceutical Group Company Limited has been granted a clinical trial notice issued by the National Medical Products Administration of the People's Republic of China, and is intended to be used for the treatment of advanced solid tumor. The specific indication will be determined after the completion of clinical research.
공고 • Dec 04Hansoh Pharmaceutical Group Company Limited Announces European Medicines Agency Accepts Review of EQRx's Marketing Authorization Application for aumolertinibThe board of directors of the Hansoh Pharmaceutical Group Company Limited announced that the European Medicines Agency (EMA) has accepted for review the partner EQRx's marketing authorization application (" MAA ") for aumolertinib, a novel, third-generation epidermal growth factor receptor-tyrosine kinase inhibitor ("EGFR-TKI") being developed and commercialized under the License Agreement, for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer ("NSCLC") with sensitizing EGFR mutations and for the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC. This is the second MAA of aumolertinib filed outside of the People's Republic of China. For details of the first MAA filed with the United Kingdom (U.K.)'s Medicines and Healthcare products Regulatory Agency ("MHRA"), please refer to the announcement of the Company dated June 15, 2022. Aumolertinib is one of the key products. As of the date of this announcement, aumolertinib has two indications approved in China and is currently under review by the MHRA for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with sensitizing EGFR mutations and for the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC. The MAA is primarily supported by data from the Phase III study (the "AENEAS Study") that evaluated aumolertinib in the first-line treatment of EGFR-mutated locally advanced or metastatic NSCLC. Aumolertinib is also currently being evaluated in several other clinical development programs for lung cancer.
Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Independent Non-Executive Director Guoqiang Lin was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Valuation Update With 7 Day Price Move • Oct 18Investor sentiment improved over the past weekAfter last week's 15% share price gain to €1.65, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 15x in the Pharmaceuticals industry in Germany. Total loss to shareholders of 41% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €2.91 per share.
Valuation Update With 7 Day Price Move • Sep 03Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to €1.75, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 16x in the Pharmaceuticals industry in Germany. Total loss to shareholders of 44% over the past three years.
Upcoming Dividend • Sep 01Upcoming dividend of HK$0.05 per shareEligible shareholders must have bought the stock before 08 September 2022. Payment date: 30 September 2022. Payout ratio is a comfortable 25% and this is well supported by cash flows. Trailing yield: 0.7%. Lower than top quartile of German dividend payers (4.7%). Lower than average of industry peers (2.8%).
Reported Earnings • Aug 27First half 2022 earnings released: EPS: CN¥0.22 (vs CN¥0.22 in 1H 2021)First half 2022 results: EPS: CN¥0.22 (up from CN¥0.22 in 1H 2021). Revenue: CN¥4.43b (flat on 1H 2021). Net income: CN¥1.30b (flat on 1H 2021). Profit margin: 29% (in line with 1H 2021). Over the next year, revenue is forecast to grow 19%, compared to a 6.6% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.
공고 • Aug 27Hansoh Pharmaceutical Group Company Limited Announces Interim Dividend for the Six Months Ended June 30, 2022, Payable on 30 September 2022Hansoh Pharmaceutical Group Company Limited announced interim dividend of HKD 0.05 per share for the six months ended June 30, 2022, payable on 30 September 2022. Record date to be 14 September 2022. Ex-dividend date to be 08 September 2022.
공고 • Aug 17Hansoh Pharmaceutical Group Company Limited to Report First Half, 2022 Results on Aug 26, 2022Hansoh Pharmaceutical Group Company Limited announced that they will report first half, 2022 results on Aug 26, 2022
Valuation Update With 7 Day Price Move • Aug 06Investor sentiment improved over the past weekAfter last week's 16% share price gain to €2.12, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 15x in the Pharmaceuticals industry in Germany. Total loss to shareholders of 11% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €4.03 per share.
Valuation Update With 7 Day Price Move • Jul 22Investor sentiment improved over the past weekAfter last week's 17% share price gain to €2.16, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 14x in the Pharmaceuticals industry in Germany. Total loss to shareholders of 9.2% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €4.06 per share.
Valuation Update With 7 Day Price Move • Jun 25Investor sentiment improved over the past weekAfter last week's 16% share price gain to €1.78, the stock trades at a forward P/E ratio of 24x. Average forward P/E is 12x in the Pharmaceuticals industry in Germany. Total loss to shareholders of 27% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €3.54 per share.